A practical deep dive into real-world use of nadofaragene firadenovec, focusing not only on trial outcomes but on how to improve tolerability, dwell time, and patient adherence in everyday practice. Drs. Merill, Schmidt, and Tyson share strategies that dramatically reduce bladder spasms and premature drug loss. Emerging real-world data on reinduction suggest meaningful additional responses, opening the door to safely delaying cystectomy in select patients. The conversation also tackles how to navigate BCG shortages, define BCG-unresponsive versus exposed disease, and strategically sequence therapies and trials to preserve future options for patients.
Contributors:
Dr. Suzanne Merrill is a urologic oncologist with Colorado Urology in Denver, Colorado.
Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.
Dr. Mark Tyson is a urologic oncologist and professor of urology with Mayo Clinic in Scottsdale, Arizona.
